CSRXP COMMENDS LAWMAKERS FOR REFOCUSING CRITICAL ATTENTION ON BIG PHARMA’S EGREGIOUS PRICE HIKES AND PRACTICES

House Committee on Oversight and Reform to Question Big Pharma Executives During Two-Day Hearing on “Unsustainable Drug Prices”

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Wednesday ahead of two days of testimony from Big Pharma executives before the U.S. House Committee on Oversight and Reform on “Unsustainable Drug Prices.” Brand name drug companies slated to appear at the hearings include Bristol Myers Squibb, Amgen and Novartis.

“CSRxP commends members of the House Oversight Committee for refocusing critical attention on the egregious pricing practices and anti-competitive tactics of Big Pharma,” said CSRxP executive director Lauren Aronson. “Big Pharma companies recently hiked prices on more than 65 brand name drugs at the height of the pandemic while the industry received billions from taxpayers for research and development and as millions of Americans faced historic economic uncertainty.”

“We encourage lawmakers to use these important hearings to generate momentum for bipartisan collaboration on market-based solutions to hold Big Pharma accountable and lower prescription drug prices,” Aronson continued. “Millions of Americans are counting on action to stop Big Pharma’s egregious price hikes and anti-competitive practices.”

Read more on the recent price hikes and egregious practices of the Big Pharma giants slated to testify at the hearing HERE.

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.